Abstract • 162

We performed 57 unrelated BMT in children of whom 35 (61 %) in HLA mismatched (MM) situation : 72 % with hematological diseases of whom 85 % malignant, 23 % LSD and 5 % CID. 3 patients (pts) were transplanted twice from same donor. Conditioning regimen included chemotherapy alone or associated to TBI plus ciclosporine and methotrexate for GVHD prophylaxis. 3 pts received T depleted marrow. Rabbit anti lymphocyte globulin (ALG) Merieux (20 mg/kg total dose) was done pre graft in most of cases (83 %). ALG was administered in 41/57 pts (72 %). (Table)

Table 1 No caption available.
Full size table

61 % of patients had malignant hemopathies in ALG group and 62 % in non ALG group : relapse free survival is respectively 87 % and 44 % at 3 years (p = 0,06). Results are good in patients who received ALG and we noticed improvement of engraftment, non increased relapse risk and GVHD percentage despite an higher number of HLA mismatches.